BP
OCUL icon

Ballentine Partners’s Ocular Therapeutix OCUL Stock Holding History

Ballentine Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-210,001
Closed -$8.82M – 161
2015
Q1 		$8.82M Buy
+210,001
New +$6.9M 0.87% 19

Other funds holding OCUL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
LCP
Lamond Capital Partners San Francisco, California $14.3M AUM 30.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ballentine Partners's OCUL Position: Q2 2015 in Review

Ballentine Partners sold out of Ocular Therapeutix (OCUL) in Q2 2015, closing a stake of 210,001 shares — an estimated $8.82M sold.

Ballentine Partners first reported a position in OCUL in Q1 2015 and held it in 1 quarter. The position peaked at $8.82M in Q1 2015. 71 funds tracked by Wall St. Rank hold OCUL as of Q2 2015.

  • Ballentine Partners reported no remaining Ocular Therapeutix position as of Q2 2015 after selling out during the quarter.
  • Ballentine Partners sold 210,001 Ocular Therapeutix shares in Q2 2015, an estimated $8.82M.
  • Ballentine Partners first reported a position in Ocular Therapeutix in Q1 2015 and held it in 1 quarter.
  • Ballentine Partners's Ocular Therapeutix position peaked at $8.82M in Q1 2015.
  • 71 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2015.

Based on Ballentine Partners's 13F filing for Q2 2015, filed 28 Jul 2015.